Cheshire, England (ots/PRNewswire) - ATTN: Health Press Most people with bipolar disorder believe that successful treatment would significantly improve their quality of life and that treatment satisfaction is achieved by efficacy and tolerability, according to final results from the large scale Thinking ...
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
Dar Es Salaam, Tanzania (ots/PRNewswire) - - The Abbott Fund and the Government of Tanzania Dedicate New Hospital Facilities to Meet Long-Term Needs of Patients with HIV/AIDS and Other Diseases In a ceremony today, Abbott CEO Miles White joined Tanzanian President Benjamin William Mkapa in dedicating a ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting ...
Lyon, France et Swiftwater, Pennsylvanie (ots/PRNewswire) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announced today the acceptance of a Biologics ...
Munich, Germany (ots/PRNewswire) - - Longer Storage Period Makes Platelets More Readily Available to European Transfusion Blood Centers European subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have received CE Mark Certification from TÜV Product Service GmbH extending the storage period ...
Durban, South Africa (ots/PRNewswire) - Trusted name Knorr is breaking new ground with Knorr Vie Shot, a naturally delicious drink bursting with fruits and vegetables. This fruit and vegetable "booster shot" is a direct response to consumers' health needs. With its focus on health and nutrition, Knorr runs an intensive consumer research program. Yet its ...
Brussels, Belgium (ots/PRNewswire) - Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the European Union, as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in children from four to sixteen years of ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today the unblinded 12 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A Summary of the results is as follows: - The study met all primary and secondary efficacy endpoints determined at 12 weeks - Efficacy endpoints were achieved with minimal side effects - No clinically ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Influenza Vaccine Leader Takes New Step in Global Pandemic Preparedness LYON, France and SWIFTWATER, Pennsylvania, September 15 /PRNewswire/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an ...
Madrid (ots/PRNewswire) - - Further Steps in the Development of Aplidin(R) in Melanoma in First Line Therapy PharmaMar announces the initiation of a programme of combination studies with Aplidin(R) (plitidepsin), PharmaMar's novel marine-derived anti-tumour agent, originally isolated from the tunicate Aplidium albicans. Aplidin(R) in Combination with Dacarbazine (DTIC) The first study is a Phase I/II ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to discontinue ...
Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.
West Haven, Connecticut, and Emeryville, California (ots/PRNewswire) - - European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Marketing Authorization Application (MAA) has been submitted by Bayer to the European Medicines Agency (EMEA) in London for the ...
Newcastle, England (ots/PRNewswire) - The Procter & Gamble Company (NYSE:PG) has been selected as the "Nondurable Household Products" industry sector leader in the global Dow Jones Sustainability Index (DJSI) listings for the sixth year in a row. The Dow Jones Sustainability Indexes (DJSI), launched in 1999, are the first global indexes tracking the financial ...
Macclesfield, England (ots/PRNewswire) - Today, new guidelines from the prestigious St. Gallen 'International Consensus Conference on the Primary Therapy of Early Breast Cancer' were released ahead of publication on the Annals of Oncology website(1). For the first time, the St. Gallen consensus panel has ...
Geneva, Switzerland (ots/PRNewswire) - - Pharmacy Channel Capability - Important Step to Oral Care Leadership The Procter & Gamble Company (NYSE: PG) today announced that it has finalised the acquisition of Sanofi-aventis' global portfolio of trusted oral care brands for an undisclosed sum. "Fluocaril and Parogencyl, are leading pharmacy brands in Europe, Asia and Africa with an incredibly loyal consumer ...
New Brunswick, New Jersey (ots/PRNewswire) - Johnson & Johnson (NYSE: JNJ) has been notified that the European Commission has cleared its proposed acquisition of Guidant Corporation (NYSE: GDT). In conjunction with the Commission's clearance, Johnson & Johnson has agreed to divest its Cordis steerable guidewires business in Europe and the Guidant Endovascular ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis (SPIRIT) trial commenced on December 2, 2004 and includes a total of 453 patients with ...
Copenhagen, Denmark (ots/PRNewswire) - - International pharmaceutical Company Chooses MCI Private IP, IP Dedicated and Colocation to Link 58 Sites Across Europe, Asia and North and South America MCI, Inc. (Nasdaq: MCIP) today announced that the international pharmaceutical company H. Lundbeck A/S has selected MCI to link 58 of its site across Europe, Asia and North and South America using MCI Private IP, a ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...
Rio De Janeiro, Brazil (ots/PRNewswire) - - Giving Patients Facing HIV Resistance Their Best Chance to Achieve Undetectable Viral Loads Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load - the optimal treatment goal for all people living with ...
Swiftwater, Pennsylvania and Lyon, France (ots/PRNewswire) - - First and Only Booster in the US for Protection Against Pertussis From Adolescence Through Adulthood Sanofi Pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announces the availability of Adacel(TM) ...
Basel, Switzerland (ots/PRNewswire) - - Results Provide New Hope in Fight Against One of the Most Deadly Cancers Treatment with the innovative cancer drug Tarceva(R) in patients with advanced non-small cell lung cancer (NSCLC) resulted in significantly longer survival compared to placebo (42.5% ...
Madrid (ots/PRNewswire) - - In his Previous Position he was Vice President, Clinical Research Oncology at OSI Pharmaceuticals in the US PharmaMar announced today the appointment of Dr. Pedro Santabárbara as Senior Director of the Clinical Development Department. Dr. Santabárbara is a medical ...
Barcelona, Spain (ots/PRNewswire) - - First Inhibitor of VEGF (a) and EGF (b) Signalling to Show Anti-Tumour Activity Both as Monotherapy and in Combination With Chemotherapy AstraZeneca today reported new findings from two Phase II studies, Trials 003 and 006, in the 2nd-line treatment of NSCLC, with ...
Barcelona, Spain (ots/PRNewswire) - AstraZeneca (LSE: AZN, NYSE: AZN) announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 - now also known by its trade name, ZACTIMA (TM). Recruitment to Phase III studies evaluating the anti-tumour activity of ZACTIMA (TM) (ZD6474) ...
World Federation for Mental Health
Vienna, Austria (ots/PRNewswire) - - World Federation for Mental Health urges better understanding, treatment and management to improve outcomes for people living with bipolar disorder The World Federation for Mental Health (WFMH) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, at the World Congress of Biological Psychiatry. The survey revealed that almost half (47%) of ...
LILLE, France and MONTREAL, Québec, June 28 (ots/PRNewswire) - The latest scientific data on MacoPharma's prion filter device will be presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) being held in Athens, Greece on July 4, 2005, MacoPharma and ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI.SV) announced ...
Philadelphia (ots/PRNewswire) - CIGNA Corporation announced today that it will appoint Paul Hartley as president of CIGNA International, reporting to CIGNA Chairman and CEO H. Edward Hanway. Hartley, who most recently served as chief executive officer of CIGNA's Asia-Pacific region, succeeds Terry Kendall, who passed away last week following a prolonged illness. ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive ...